A Randomized, Open-Label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients

Trial Profile

A Randomized, Open-Label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Therapeutic Use
  • Acronyms VICTOR
  • Sponsors Roche
  • Most Recent Events

    • 16 Feb 2016 Results published in the Clinical Infectious Diseases
    • 01 May 2009 Long-term results have been published in the American Journal of Transplantation.
    • 01 Sep 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top